Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study.

Area of Science:

• Pharmacology
• Neurology
• Clinical Pharmacy

Background:

• Epilepsy management often involves carbamazepine (CBZ), a widely used antiepileptic drug.
• Conventional CBZ formulations can lead to suboptimal seizure control and intermittent side effects.
• Improving CBZ tolerability and pharmacokinetic profiles is crucial for patient adherence and therapeutic outcomes.

Purpose of the Study:

• To assess the tolerability and pharmacokinetics of a novel controlled-release (CR) carbamazepine (CBZ) formulation.
• To compare the efficacy and side effect profile of CR CBZ against conventional CBZ in epileptic patients.
• To evaluate the impact of CR CBZ on plasma concentration fluctuations of CBZ and its epoxide metabolite.

Main Methods:

• A multicentre, double-blind, cross-over trial involving 48 epileptic patients on conventional CBZ monotherapy.
• Patients were randomized to receive either conventional CBZ or CR CBZ in a sequential manner with individualized dosing.
• Pharmacokinetic profiles (plasma CBZ and CBZ-epoxide concentrations), tolerability, and efficacy were evaluated over two treatment periods.

Main Results:

• The mean daily dose of CBZ increased by 16% with the CR formulation.
• CR CBZ significantly reduced daily fluctuations in plasma carbamazepine and carbamazepine-epoxide levels (p < 0.001).
• Intermittent side effects were significantly decreased with CR CBZ (6 patients) compared to conventional CBZ (26 patients) (p < 0.001).

Conclusions:

• The controlled-release (CR) formulation of carbamazepine (CBZ) offers improved tolerability and pharmacokinetic stability.
• CR CBZ significantly reduces intermittent side effects and allows for less frequent dosing regimens.
• This novel CR formulation represents a promising advancement in the management of epilepsy.